Ticker

Aldeyra Therapeutics (NASDAQ: ALDX - Get Free Report) and Grifols (NASDAQ: GRFS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Volatility and Risk Aldeyra Therapeutics has a beta of

OTTAWA, March 30, 2026 (GLOBE NEWSWIRE) -- Proponents of public universal health care across Canada are calling for the closure of Grifols facilities in the wake of two deaths in Winnipeg of people who sold their plasma to the giant multinational. A third person is suing the hugely profitable Grifols for kidney damage from a plasma sale. Health Canada also reports non-compliance at four other Grifols sites.

Healthcare ​company Grifols ‌said ​on ​Tuesday it ⁠has ​approved ​a U.S. ​initial ​public offering of ‌its ⁠U.S. biopharma ​business.

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease (PD) occur more than a decade before clinical diagnosis, with potential future implications for early…

TORONTO, March 13, 2026 (GLOBE NEWSWIRE) -- The Ontario and Manitoba Health Coalitions held a press conference this morning to respond to a  report from CBC  about two patients who died in Winnipeg after having their blood plasma harvested at centres owned by for-profit pharmaceutical corporation Grifols.  Another report followed, of a man who is suing , alleging kidney damage from equipment failure while having his…